Lou Gehrig's Disease

Published by	Global Industry Analysts, Inc.
Published	April, 2010	Product code	121108
Content info	Pages: 258
Price	US $ 3450 PDF by E-mail (Single user license) US $ 10350 PDF By E-mail (Global License to Company and its Fully-owned Subsidiaries)

Introduction
Related Reports

Lou Gehrig's Disease published by Global Industry Analysts, Inc. in April, 2010. This report consists of Pages: 258 and the price starts from US $ 3450.

Introduction

Abstract

This report analyzes the Global market for Lou Gehrig' s Disease in US$ Million. Annual estimates and forecasts are provided for the period 2006 through 2015. The report profiles 37 companies including many key and niche players such as Aeolus Pharmaceuticals, Inc., Amorfix Life Sciences Ltd., Avicena Group, Inc., Ceregene, Inc., CytRx Corporation, Genzyme Corporation, Isis Pharmaceuticals, Inc., Knopp Neurosciences, Maas Biolab, NeuroNova AB, Sygnis Pharma AG, Teva Pharmaceutical Industries Ltd., and Trophos SA. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

Global Market Analysis
Sanofi-Aventis - The Only Drug Maker for ALS
Rilutek
Prevalence and Incidence of ALS
The United States
Canada
Table 1: Mortality Rate of ALS in Canada - A Historic Review (includes corresponding Graph/Chart)
The United Kingdom
New Zealand
Australia
Table 2: Mortality Rate in Australia for Years 2005 through 2007(includes corresponding Graph/Chart)

2. AMYOTROPHIC LATERAL SCLEROSIS -

AN INSIGHT

Major Types of ALS
Etiology
Exact Causes of ALS Still Unknown
Major Milestones in ALS Treatment Arena
Diagnosis
Symptoms of ALS
Initial symptoms
Emerging Symptoms
Use of BiPAP, IPPV and Mechanical Respirators in ALS
Measures to Deal with ALS Problems
Treatment
Symptomatic Treatment

3. POTENTIAL THERAPIES FOR ALS

Neurotrophic Factors
Insulin-like Growth Factor
Vascular endothelial growth factor
Sangamo BioSciences to Develop SB 509
Smaller Molecules
RNA Interference
Stem Cells Offer New Hope
Studies on Stem Cells
LTC to Develop New Lou Gehrig' s Disease Models
Herbal Treatment
Lithium: A potential Treatment for ALS
Advancements in ALS Genetics
Select Pipeline Drugs for ALS Under Clinical Trials (2009)

4. CLINICAL TRIALS AND RESEARCH STUDIES

CytRx Initiates Phase 2/3 Clinical Trial for Arimoclomol
New Treatment for ALS Patients
KNS-760704 Receives Orphan Designation
KNS-760704 Enters Phase 2 Study
Maas Biolab SBIR Initiates Phase 2 for Cyclosporin
Researchers Identify New Gene for ALS

5. RECENT INDUSTRY ACTIVITY

Merck to Purchase Insmed' s Assets
NeuroNova Signs Agreement with Genentech
Insmed Inks a Deal with IDIS to Organize NPPs for IPLEXTM
Teva to Extend Branded Products in Niche Specialty Diseases
Asklepios and ALS TDI Develop Latest Therapeutic Delivery Alternatives for ALS Treatment
Medicare Extends DME Coverage of HFCWO to Cure Neuromuscular Disorders
Neuralstem and Hospital of Taiwan Collaborate for Development of Neural Stem Cell Therapies
Life Technologies to Create Neurodegenerative Disease Models
Medicare Extends the Coverage of HFCWO to Cure Neuromuscular Disorders
Sygnis Obtains Orphan Drug Status for AX200 in Spinal Cord Injury Treatment
Insmed Obtains Royalty-Free Global Rights for IPLEXTM
Q Therapeutics Collaborates with Johns Hopkins Research Team
Aldagen to Collaborate with UC Davis
ALS TDI Collaborates with CSC
ALS TDI and Allen Institute for Brain Science Enter into Agreement
Amorfix Completes Research Partnership with Biogen Idec
Isis Receives Orphan Drug Designation
Prize4Life Endorses BrainStorm to Develop ALS Cure
ALS TDI Selects Microbix to Manufacture Adenoviruses
Maas BiolAB Receives SBIR Grant
Neuralstem Collaborates with University of Michigan
ALS TDI and MDA Collaborate

6. PLAYERS VENTURING THE ALS MARKET

Aeolus Pharmaceuticals, Inc. (US)
Amorfix Life Sciences Ltd. (Canada)
Avicena Group, Inc. (US)
Ceregene, Inc. (US)
CytRx Corporation (US)
Genzyme Corporation (US)
Isis Pharmaceuticals, Inc. (US)
Knopp Neurosciences (US)
Maas Biolab (US)
NeuroNova AB (Sweden)
Sygnis Pharma AG (Germany)
Teva Pharmaceutical Industries Ltd. (Israel)
Trophos SA (France)

7. ASSOCIATIONS INVOLVED IN ALS

RESEARCH

Northeast Amyotrophic Lateral Sclerosis Consortium (US)
Muscular Dystrophy Association (MDA)
The ALS Association
ALS Society of Canada
ALS Therapy Development Institute
Motor Neurone Disease Research Institute of Australia

8. GLOBAL MARKET PERSPECTIVE

Table 3: World Recent Past, Current & Future Analysis for Lou Gehrig' s Disease by Geographic Region - US, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 4: World 10-Year Perspective for Lou Gehrig' s Disease by Geographic Region -Percentage Breakdown of Sales for US, and Rest of World Markets for Years 2006, 2009 & 2015